LB Bohle – 10.06.2025
Nipro Vialex – 26th January 2025
PCI – 7th June 2024
Temax_Krautz

Current Edition

Nasal & Pulmonary Drug Development
Novo Nordisk 20 March 2024, 11:21
Carterra – 24th March 2025
Bespak – 21.05.2025
Stoelzle – 15th May 2025

Improving Outcomes for Gastric Cancer Patients via a Novel Oral Daily Dose Chemotherapy Formulation, Oncoral

Gastric cancer is the fifth most common cancer, with around one million annual incidences worldwide, and it represents the fourth most common cause of cancer deaths. High incidences of the disease in Asia mean that screening in countries like Japan have made survival rates better than in Western countries, where the disease is often already advanced by the time of diagnosis. The gastric cancer drug market is growing rapidly and is expected to approach USD 4 billion by 2029 according to GlobalData. Carl Bjartmar at Ascelia Pharma analyses why this growth, is fuelled by several factors, including an increase in the overall incidence, as well as higher treatment rates and extended treatment duration.

Scott Pharma – 25.03.2025
SMI – 24/03/2025
FujiFilm Skyscraper: 26th November 2024
Woolcool 26 March 2024, 16:16
Biopharma group 6 March 2024, 09:40
EyeC 18 March 2024, 13:10
Nipro – 09.06.2025
L.B. Bohle – 08.04.2025